Dogwood Therapeutics, Inc. (Nasdaq: DWTX) reported its first quarter 2026 financial results on May 14, 2026, revealing a net loss of $5.0 million, or $0.15 per share, compared to a net loss of $12.2 million, or $8.45 per share, in the same period in 2025. The company, which focuses on developing first-in-class non-opioid medicines to treat pain and neuropathy, provided updates on its pipeline candidates, Halneuron and SP16, which are advancing toward key clinical milestones.
CEO Greg Duncan emphasized the company's strong operational start to 2026, driven by pipeline progress. The Phase 2b study of Halneuron, a non-opioid NaV 1.7 inhibitor for chemotherapy-induced neuropathic pain (CINP), has enrolled 164 patients, with top-line results expected in fall 2026. Halneuron has received Fast Track designation from the FDA for CINP. Additionally, SP16, a low-density lipoprotein receptor related protein-1 agonist, received IND approval from the FDA for the treatment of chemotherapy-induced pain and peripheral neuropathy (CIPPN). The Phase 1b trial, fully funded by the National Cancer Institute, is set to begin enrollment in mid-2026 at the University of Virginia.
The company also executed a global development license for its legacy combination antiviral assets, further strengthening its portfolio. Financially, Dogwood completed a financing of up to $26.9 million in January 2026 to support Halneuron's development, with gross proceeds of $12.5 million received. Cash on hand stood at $13.2 million as of March 31, 2026, providing operational runway into the fourth quarter of 2026.
Research and development expenses for the first quarter were $2.7 million, up from $2.4 million in the prior year, driven by increased drug development costs for Halneuron and personnel costs. General and administrative expenses rose to $2.4 million from $2.0 million, primarily due to higher salaries and personnel costs.
The significance of Dogwood's pipeline lies in its focus on non-opioid alternatives for pain management, addressing a critical need amid the opioid crisis. Halneuron, as a NaV 1.7 inhibitor, targets a specific mechanism for pain reduction, while SP16's LRP1 agonism offers potential for nerve repair and anti-inflammatory effects. Both candidates aim to treat chemotherapy-induced neuropathy, a common and debilitating side effect of cancer treatment. The upcoming data readouts could position Dogwood as a key player in the pain therapeutics market, offering new options for patients who currently rely on opioids or have limited treatment options.
For more information, visit www.dwtx.com.
